High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer

被引:2
|
作者
Olmez, Fatma [1 ]
Oglak, Suleyman Cemil [2 ]
Olmez, Omer Fatih [3 ]
Akbayir, Ozgur [4 ]
Yilmaz, Ercan [5 ]
Akgol, Sedat [6 ]
Konal, Merve [7 ]
Seyhan, Niyazi Alper [8 ]
Kinter, Alp Koray [4 ]
机构
[1] Univ Hlth Sci Turkey, Kanuni Sultan Suleyman Training & Res Hosp, Clin Obstet & Gynecol, Istanbul, Turkey
[2] Univ Hlth Sci Turkey, Gazi Yasargil Training & Res Hosp, Clin Obstet & Gynecol, Diyarbakir, Turkey
[3] Istanbul Medipol Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey
[4] Univ Hlth Sci Turkey, Prof Dr Cemil Tascioglu City Hosp, Clin Gynecol Oncol, Istanbul, Turkey
[5] Inonu Univ, Dept Obstet & Gynecol, Fac Med, Malatya, Turkey
[6] Univ Hlth Sci Turkey, Kanuni Sultan Suleyman Training & Res Hosp, Clin Gynecol Oncol, Istanbul, Turkey
[7] Kocaeli Univ, Dept Gynecol Oncol, Fac Med, Kocaeli, Turkey
[8] Adnan Menderes Univ, Dept Gynecol Oncol, Fac Med, Aydin, Turkey
关键词
High-grade serous ovarian cancer; programmed death-1 receptor; tumor-infiltrating lymphocytes; INFILTRATING T-CELLS; PROGNOSTIC-SIGNIFICANCE; NEOADJUVANT CHEMOTHERAPY; FAVORABLE PROGNOSIS; LYMPHOCYTES; DEATH-1; CD103;
D O I
10.4274/tjod.galenos.2022.59558
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The current study assesss programmed death-1 (PD-1) receptor expression and CD3, CD4, and CD8 tumor-infiltrating lymphocytes (TILs) in high-grade serous ovarian cancer (HGSOC) and to associate our results with neoadjuvant chemotherapy history and disease prognosis. Materials and Methods: We included cases diagnosed with primary HGSOC with biopsy or surgical resection materials in this study. The immunoreactivity of CD3, CD4, CD8, and PD1 was assessed immunohistochemically in tumor tissue. We analyzed TILs in two predetermined groups of high and low TIL. The relationships between clinical characteristics, PD-1, and TIL were assessed. by the chi((2)) test or Fisher's Exact test. We used Kaplan-Meier survival analysis and Cox proportional hazards regression model to the connection between survival and the amounts of TIL, and PD1. Results: Univariate analysis demonstrated that optimal debulking (p<0.001), early International Federation of Gynecology and Obstetrics stage (p=0.046), and higher scores of stromal CD8+ TIL expression (p=0.028) in tumor cells were all substantially correlated with longer disease-free survival (DFS), whereas the remaining variables analyzed, including PD-1 positivity, stromal CD3+, and CD4+ TILs, and intraepithelial CD3+, CD4+, and CD8+ TILs, were not correlated with DFS. Also, univariate analysis revealed that optimal debulking (p=0.010), and higher scores of stromal CD8+ TIL expression (p=0.021) in tumor cells were all substantially correlated with longer overall survival (OS). Conclusion: Higher scores of stromal CD8+ TILs are substantially correlated with DFS and OS in univariate analyses, whereas scores of stromal CD3+ and CD4+ TILs, and intraepithelial CD3+, CD4+, and CD8+ TILs are not correlated with DFS and OS in both univariate and multivariate analyses. Also, we found a significant association between PD-1 positivity and the scores of stromal CD3+ TILs and intraepithelial CD8+ TILs. However, no remarkable relationship was revealed between PD-1 positivity and the survival of HGSOC cases.
引用
收藏
页码:246 / 256
页数:11
相关论文
共 50 条
  • [1] Nuclear Elf-3 expression in high-grade serous ovarian cancer is associated with patient survival
    Mok, Samuel
    Ghosh, Sue
    Kwong, Joseph
    Welch, William
    Gershenson, David
    Birrer, Michael
    Wong, Kwong-Kwok
    [J]. CANCER RESEARCH, 2009, 69
  • [2] PD-1/PD-L1 EXPRESSION AND TUMOR-INFILTRATING LYMPHOCYTES ARE PROGNOSTICALLY FAVORABLE IN HIGH-GRADE SEROUS OVARIAN CANCER
    de la Fuente, L. Martin
    Fremer, S. Westbom
    Arildsen, N. Skovbjerg
    Hartman, L.
    Malander, S.
    Kannisto, P.
    Masback, A.
    Hedenfalk, I.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 761 - 761
  • [3] The expression of PD-1/PD-L1 in high-grade serous ovarian carcinoma and its metastases
    Unger, C.
    Bronsert, P.
    Juhasz-Boess, I
    Kurowski, K.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10) : E175 - E175
  • [4] Differential nuclear Elf-3 expression in high-grade serous ovarian cancer is associated with patient survival
    Yeung, T.
    Ghosh, S.
    Wong, K.
    Gutierrez-Hartmann, A.
    Kwong, J.
    Welch, W.
    Gershenson, D.
    Birrer, M.
    Mok, S.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S17 - S18
  • [5] Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis
    Tao Zhang
    Xin Zhou
    Xiaofei Zhang
    Shuang Niu
    Hao Chen
    Feng Zhou
    [J]. Virchows Archiv, 2023, 482 : 755 - 766
  • [6] PD-L1 Expression in High-Grade Serous and Clear Cell Ovarian Cancer
    Ljubiša Jovanović
    Andja Ćirković
    Milena Jović
    Radmila Janković
    [J]. Indian Journal of Gynecologic Oncology, 2022, 20
  • [7] Modeling the tumor microenvironment of high-grade serous ovarian cancer.
    Balkwill, Frances
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (13) : 22 - 22
  • [8] PD-L1 Expression in High-Grade Serous and Clear Cell Ovarian Cancer
    Jovanovic, Ljubisa
    Cirkovic, Andja
    Jovic, Milena
    Jankovic, Radmila
    [J]. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 20 (04)
  • [9] Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
    Hanker, L. C.
    El-Balat, A.
    Drosos, Z.
    Kommoss, S.
    Karn, T.
    Holtrich, U.
    Gitas, G.
    Graeser-Mayer, M.
    Anglesio, M.
    Huntsman, D.
    Rody, A.
    Gevensleben, H.
    Hoellen, F.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1421 - 1430
  • [10] Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
    L. C. Hanker
    A. El-Balat
    Z. Drosos
    S. Kommoss
    T. Karn
    U. Holtrich
    G. Gitas
    M. Graeser-Mayer
    M. Anglesio
    D. Huntsman
    A. Rody
    H. Gevensleben
    F. Hoellen
    [J]. Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1421 - 1430